Cargando…

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy

GO is the most frequent extrathyroidal manifestation of Graves’ disease, although it may rarely occur in euthyroid/hypothyroid patients with chronic autoimmune thyroiditis. It is a relatively infrequent disorder, and men tend to have more severe ocular involvement at an older age. The prevalence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartalena, Luigi, Piantanida, Eliana, Gallo, Daniela, Lai, Adriana, Tanda, Maria Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734282/
https://www.ncbi.nlm.nih.gov/pubmed/33329408
http://dx.doi.org/10.3389/fendo.2020.615993
_version_ 1783622442217897984
author Bartalena, Luigi
Piantanida, Eliana
Gallo, Daniela
Lai, Adriana
Tanda, Maria Laura
author_facet Bartalena, Luigi
Piantanida, Eliana
Gallo, Daniela
Lai, Adriana
Tanda, Maria Laura
author_sort Bartalena, Luigi
collection PubMed
description GO is the most frequent extrathyroidal manifestation of Graves’ disease, although it may rarely occur in euthyroid/hypothyroid patients with chronic autoimmune thyroiditis. It is a relatively infrequent disorder, and men tend to have more severe ocular involvement at an older age. The prevalence of GO is lower than in the past among patients with recent onset Graves’ hyperthyroidism, and moderate-to-severe forms requiring aggressive treatments are no more than 5–6% of all cases of GO. After an initial inflammatory (active) phase and a phase of stabilization (plateau phase), GO tends to improve and eventually inactivates (inactive or burnt-out phase). Minimal-to-mild GO often remits spontaneously, but complete restitutio ad integrum almost never occurs when GO is more than mild. Several risk factors contribute to its development on a yet undefined genetic background. Cigarette smoking is the most important of them. Early diagnosis, control and removal of modifiable risk factors, early treatment of mild forms of GO may effectively limit the risk of progression to more severe forms, which have a profound and dramatic impact on the quality of life of affected individuals, and remain a therapeutic challenge, often requiring long-lasting and multiple medical and surgical therapies.
format Online
Article
Text
id pubmed-7734282
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77342822020-12-15 Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy Bartalena, Luigi Piantanida, Eliana Gallo, Daniela Lai, Adriana Tanda, Maria Laura Front Endocrinol (Lausanne) Endocrinology GO is the most frequent extrathyroidal manifestation of Graves’ disease, although it may rarely occur in euthyroid/hypothyroid patients with chronic autoimmune thyroiditis. It is a relatively infrequent disorder, and men tend to have more severe ocular involvement at an older age. The prevalence of GO is lower than in the past among patients with recent onset Graves’ hyperthyroidism, and moderate-to-severe forms requiring aggressive treatments are no more than 5–6% of all cases of GO. After an initial inflammatory (active) phase and a phase of stabilization (plateau phase), GO tends to improve and eventually inactivates (inactive or burnt-out phase). Minimal-to-mild GO often remits spontaneously, but complete restitutio ad integrum almost never occurs when GO is more than mild. Several risk factors contribute to its development on a yet undefined genetic background. Cigarette smoking is the most important of them. Early diagnosis, control and removal of modifiable risk factors, early treatment of mild forms of GO may effectively limit the risk of progression to more severe forms, which have a profound and dramatic impact on the quality of life of affected individuals, and remain a therapeutic challenge, often requiring long-lasting and multiple medical and surgical therapies. Frontiers Media S.A. 2020-11-30 /pmc/articles/PMC7734282/ /pubmed/33329408 http://dx.doi.org/10.3389/fendo.2020.615993 Text en Copyright © 2020 Bartalena, Piantanida, Gallo, Lai and Tanda http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Bartalena, Luigi
Piantanida, Eliana
Gallo, Daniela
Lai, Adriana
Tanda, Maria Laura
Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
title Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
title_full Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
title_fullStr Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
title_full_unstemmed Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
title_short Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
title_sort epidemiology, natural history, risk factors, and prevention of graves’ orbitopathy
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734282/
https://www.ncbi.nlm.nih.gov/pubmed/33329408
http://dx.doi.org/10.3389/fendo.2020.615993
work_keys_str_mv AT bartalenaluigi epidemiologynaturalhistoryriskfactorsandpreventionofgravesorbitopathy
AT piantanidaeliana epidemiologynaturalhistoryriskfactorsandpreventionofgravesorbitopathy
AT gallodaniela epidemiologynaturalhistoryriskfactorsandpreventionofgravesorbitopathy
AT laiadriana epidemiologynaturalhistoryriskfactorsandpreventionofgravesorbitopathy
AT tandamarialaura epidemiologynaturalhistoryriskfactorsandpreventionofgravesorbitopathy